Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatment Dapiglutide was assessed to be well-tolerated Tolerability profile observed suggests doses investigated were at the lower end of the therapeutic range Much higher doses of dapiglutide are being investigated in the ongoing 13-week Phas ...